APPHD Stock Overview
Engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Apontis Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.37 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.69 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| APPHD | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 0.6% |
| 1Y | n/a | -5.1% | 4.6% |
Return vs Industry: Insufficient data to determine how APPHD performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how APPHD performed against the UK Market.
Price Volatility
| APPHD volatility | |
|---|---|
| APPHD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: APPHD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine APPHD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 177 | Bruno Wohlschlegel | apontis-pharma.de |
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
Apontis Pharma AG Fundamentals Summary
| APPHD fundamental statistics | |
|---|---|
| Market cap | €72.14m |
| Earnings (TTM) | -€11.30m |
| Revenue (TTM) | €36.96m |
2.0x
P/S Ratio-6.4x
P/E RatioIs APPHD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APPHD income statement (TTM) | |
|---|---|
| Revenue | €36.96m |
| Cost of Revenue | €13.79m |
| Gross Profit | €23.17m |
| Other Expenses | €34.47m |
| Earnings | -€11.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 09, 2024
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 62.68% |
| Net Profit Margin | -30.58% |
| Debt/Equity Ratio | 19.9% |
How did APPHD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/22 23:52 |
| End of Day Share Price | 2024/03/25 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apontis Pharma AG is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Orquera | First Berlin Equity Research GmbH |
| Tim Wunderlich | Hauck Aufhäuser Investment Banking |
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |